Abstract: The present invention includes compositions and methods of making a nanoparticle composition comprising a polymeric core comprising one or more polymers and one or more active agents, and at least one layer of one or more lipids on the surface of the polymeric core; more specifically, the invention relates to the use of curcumin within such a lipid-polymer nanoparticle formulation for minimizing QT prolongation associated with curcumin in treatment of cancer.
Type:
Grant
Filed:
August 31, 2013
Date of Patent:
September 22, 2015
Assignees:
University of North Texas Health Science Center at Fort Worth, SignPath Pharma, Inc.
Inventors:
Amalendu Prakash Ranjan, Anindita Mukerjee, Jamboor K. Vishwanatha, Lawrence Helson
Abstract: Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease.
Type:
Grant
Filed:
December 19, 2012
Date of Patent:
May 19, 2015
Assignees:
Arphios Corporation, For the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College acting on behalf of Louisiana State University Health Sciences Center at Shreveport
Inventors:
Trevor Percival Castor, Jonathan Steven Alexander, Geoffrey Purdum, J. David Rios, Lisa M. Schrott, Theodore A. Tyler, Maria I. Vizcaino
Abstract: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.
Type:
Grant
Filed:
April 11, 2008
Date of Patent:
May 5, 2015
Assignee:
University of North Texas Health Science Center at Fort Worth
Inventors:
Arthur R. C. Braden, Jamboor K. Vishwanatha
Abstract: The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption. The present invention also provides products and methods for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition in a location within the body of a patient.
Type:
Grant
Filed:
November 5, 2008
Date of Patent:
March 31, 2015
Assignees:
Nanocopoeia, Inc., Louisiana State University Health Sciences Center Office of Research
Inventors:
Tammy R. Dugas, Alok Khandelwal, James John Kleinedler, III, John Devlin Foley
Abstract: The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption. The present invention also provides products and methods for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition in a location within the body of a patient.
Type:
Grant
Filed:
October 2, 2012
Date of Patent:
March 31, 2015
Assignees:
Nanocopoeia, Inc., Louisiana State University Health Sciences Center Office of Research
Inventors:
Tammy R. Dugas, Alok Khandelwal, James John Kleinedler, John Devlin Foley
Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.
Type:
Grant
Filed:
October 25, 2013
Date of Patent:
November 25, 2014
Assignees:
University of North Texas Health Science Center at Fort Worth, The Board of Regents of the University of Texas System
Abstract: The invention provides a novel strain of HIV-2 capable of causing immunodeficiency. The invention also provides compositions comprising the nucleic acids and polypeptides characteristic of this HIV-2 virus, antibodies specific for this HIV-2 virus, methods of using these compositions, and methods of detecting HIV-2 virus.
Type:
Application
Filed:
April 28, 2014
Publication date:
August 21, 2014
Applicant:
Tulane University Health and Sciences Center
Abstract: The claimed invention is directed toward an HIV-2 isolate designated NWK08F, including variants, and isolated proteins and nucleotides obtained from said isolates.
Type:
Grant
Filed:
November 13, 2009
Date of Patent:
June 10, 2014
Assignee:
Tulane University Health Sciences Center
Abstract: Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved D3 receptor affinity and selectivity, as well as water solubility, is achieved. A series of linking-chain derivatives are disclosed wherein functionality such as OH or OAc groups have been introduced into the linking chain. In general, these modifications are well tolerated at D3 receptors and achieve high selectivity over D2 and D4 receptors.
Type:
Grant
Filed:
June 15, 2007
Date of Patent:
June 10, 2014
Assignees:
The United States of America as Represented by the Secretary of the Department of Health and Human Services, The University of North Texas Health Science Center at Fort Worth
Inventors:
Amy Hauck Newman, Peter Grundt, George C. Cyriac, Robert Luedtke, Jianjing Cao
Abstract: The present invention relates to novel compositions and uses thereof as antioxidants and/or neuroprotective agents for the treatment of medical conditions associated with oxidative stress and/or neural damage, such as, for example, neurological diseases, disorders and trauma, and hence in the treatment of CNS-associated diseases, disorders and trauma.
Type:
Application
Filed:
September 23, 2011
Publication date:
May 29, 2014
Applicant:
University of North Texas Health Science Center
Inventors:
James W. Simpkins, Yi Wen, Shaohua Yang
Abstract: Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.
Type:
Grant
Filed:
November 17, 2009
Date of Patent:
May 27, 2014
Assignees:
University of North Texas Health Science Center at Fort Worth, The Board of Regents, The University of Texas System
Inventors:
Anil K. Sood, Andras G. Lacko, Gabriel Lopez-Berestein, Lingegowda S. Mangala, Walter J. McConathy, Laszlo Prokai, Maya P. Nair
Abstract: A tracking device configured to be coupled to an interventional instrument and tracked by a magnetic resonance imaging system is provided. The tracking device includes, for example, paramagnetic and diamagnetic components that form first and second tracking members. When the tracking device is adjusted into a first arrangement, the tracking device will produce a local magnetic field in the presence of the magnetic field of an MRI system that is measurable by the MRI system. However, when the tracking device is adjusted into a second arrangement, the local magnetic field produced by the tracking device is reduced relative to the first arrangement, wherein the reduced local magnetic field produces substantially no magnetic field disturbances detectable by the MRI system. Images may be acquired of a patient in which the tracking device has been introduced and, using a numerical fitting method, an accurate location of the tracking device can be determined.
Type:
Grant
Filed:
December 22, 2010
Date of Patent:
March 18, 2014
Assignee:
Sunnybrook Health Sciences Center
Inventors:
Charles H. Cunningham, William Dominquez-Viqueira
Abstract: The present invention includes compositions and methods of making a nanoparticle composition comprising a polymeric core comprising one or more polymers and one or more active agents, and at least one layer of one or more lipids on the surface of the polymeric core; more specifically, the invention relates to the use of curcumin within such a lipid-polymer nanoparticle formulation for minimizing QT prolongation associated with curcumin in treatment of cancer.
Type:
Application
Filed:
August 31, 2013
Publication date:
March 6, 2014
Applicants:
SignPath Pharma Inc., University of North Texas Health Science Center
Inventors:
Amalendu Prakash Ranjan, Anindita Mukerjee, Jamboor K. Vishwanatha, Lawrence Helson
Abstract: An isolated nucleic acid molecule that selectively binds to an E-selectin protein comprises a contiguous 29-30 nucleotide sequence that includes at least one monothiophosphate or a dithiophosphate modified nucleotide. Also disclosed are methods of inhibiting an E-selectin mediated interaction with a natural E-selectin ligand, and methods of targeting an imaging agent or therapeutic agent to a target tissue bearing E-selectin.
Type:
Grant
Filed:
August 15, 2011
Date of Patent:
February 25, 2014
Assignee:
The University of Texas Health Science Center
Inventors:
David G. Gorenstein, Takemi Tanaka, Anoma Somasunderam, Aman Mann
Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.
Type:
Application
Filed:
October 25, 2013
Publication date:
February 20, 2014
Applicants:
The Board of Regents of the University of Texas System, University of North Texas Health Science Center at Fort Worth
Abstract: The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.
Type:
Application
Filed:
August 7, 2013
Publication date:
February 13, 2014
Applicants:
National Institutes of Health, University of North Texas Health Science Center
Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.
Type:
Grant
Filed:
April 16, 2008
Date of Patent:
November 5, 2013
Assignees:
University of North Texas Health Science Center at Fort Worth, The Board of Regents of the University of Texas System
Abstract: The invention relates to point of care diagnostic disposables, devices, methods, and systems for diagnosing or predicting prostate cancer. The present invention employs biomarker specific reagents in disposable cassettes or lab cards for use as analyzers, as well as software to evaluate and report test results. The system promises to improve point of care in vitro diagnostics.
Type:
Application
Filed:
November 11, 2011
Publication date:
October 17, 2013
Applicants:
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, WILLIAM MARSH RICE UNIVERSITY
Inventors:
John T. McDevitt, Nicolaos Christodoulides, Pierre N. Floriano, Ian Thompson
Abstract: The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those suitable for topical or systemic administration. Methods of using the multimeric Tie 2 agonists of the invention for stimulating angiogenesis and for promoting healing of wounds, such as diabetic ulcers or skin grafts, are also provided.